No matter what WGT says. This price is extremely high. It doesn't matter where anything is in any process. The fact of the matter is that the company doesn't have a drug approval. It has mediocre results and provides an unpredictable future. Therefore the price is really high and overvalued. Also I wouldn't include yourself in "us'" when referring to the prediction of the share price hit. People can thank me, biochecker, kund, and squid for the realistic expectations.
Market Data 
Markets 
AI
